The Human Papillomavirus E6 Protein
DOI:
https://doi.org/10.61173/xszfkn89Keywords:
E6 protein, Human Papillomavirus, cancerAbstract
The association of human papillomavirus (HPV) infection with various forms of cancer, including oropharyngeal, cervical, and anal cancers, presents a significant global health concern. The HPV E6 oncoprotein plays a crucial role in promoting carcinogenesis by disrupting key cellular pathways involved in cell cycle control, apoptosis, and immune evasion. This review provides a comprehensive analysis of the molecular mechanisms by which HPV E6 induces cancer, with a particular focus on its association with cellular proteins and its role in the progression of malignancies associated with HPV. Additionally, therapeutic approaches targeting HPV E6 are discussed, including small molecule inhibitors, RNA interference strategies, and immunotherapies. These therapeutic modalities show promising potential for selectively targeting HPV-infected cancer cells and improving treatment outcomes for HPV-associated malignancies, particularly cervical cancer. Overall, understanding the molecular mechanisms driven by HPV E6 is essential for the development of targeted therapies and preventive strategies against HPV-induced cancers.
References
[1] de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004 Jun 20;324(1):17-27.
[2] Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020 Jul;40(5):602-608. doi: 10.1080/01443615.2019.1634030. Epub 2019 Sep 10. Erratum in: J Obstet Gynaecol. 2020 May;40(4):590.
[3] Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014; 10:2147–2162.
[4] Nygard M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, Sigurdardottir LG, Vuocolo S, Kjaer SK, Dillner J. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015; 22:943–948.
[5] Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018 Aug 6;36(32 Pt A):4768- 4773.
[6] Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis. 2007 Sep 1;45(5):609-7.
[7] Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020 Jul 16;8(3):391.
[8] Tomaić V. Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites. Cancers (Basel). 2016 Oct 19;8(10):95.
[9] Ansari T, Brimer N, Vande Pol SB. Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53. J Virol. 2012 Oct;86(20):11386-91.
[10] He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, Khokhar AR, Kuang J. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene. 2005 Apr 21;24(18):2929-43.
[11] Pal A, Kundu R. Human Papillomavirus E6, and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020 Jan 21;10:3116.
[12] Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020 Jan 21;10:3116.
[13] Jung HS, Rajasekaran N, Ju W, Shin YK. Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. J Clin Med. 2015 May 21;4(5):1126-55.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
